v3.26.1
Licensed Rights and Other Intangible Assets (Tables)
6 Months Ended
Jun. 30, 2026
Licensed Rights and Other Intangible Assets [Abstract]  
Schedule of License Rights and Other Intangible Assets, Net

The following provides information about our license rights and other intangible assets, net as of June 30, 2026 and December 31, 2025 (in thousands):

 

    June 30, 2026     December 31, 2025  
    Gross Carrying Amount     Accumulated Amortization     Net     Gross Carrying Amount     Accumulated Amortization     Net  
Intangible assets subject to amortization:                                                
Hormone therapy drug patents   $ 5,716     $ 2,612     $ 3,104     $ 5,695     $ 2,423     $ 3,272  
Hormone therapy drug patents applied
and pending approval
    146             146       180             180  
Intangible assets subject to amortization     5,862       2,612       3,250       5,875       2,423       3,452  
Intangible assets not subject to amortization:                                                
Trademarks/trade name rights     309             309       309             309  
License rights and other intangible assets, net   $ 6,171     $ 2,612     $ 3,559     $ 6,184     $ 2,423     $ 3,761  
Schedule of Intangible Assets Subject to Amortization

Our intangible assets subject to amortization are expected to be amortized as follows (in thousands):

 

Year ending December 31,    
2026   $ 194  
2027     383  
2028     384  
2029     383  
2030     383  
Thereafter     1,377  
Total   $ 3,104